Kura Oncology Logo
Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020
07 mai 2020 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Logo
Kura Oncology Announces Commencement of Public Offering of Common Stock
05 mai 2020 16h01 HE | Kura Oncology, Inc.
SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Logo
Kura Oncology Reports First Quarter 2020 Financial Results
04 mai 2020 16h05 HE | Kura Oncology, Inc.
– Enhanced focus on tipifarnib in HRAS mutant HNSCC and KO-539 menin inhibitor in NPM1-mutant and KMT2A(MLL)-rearranged AML – – Three abstracts accepted for presentation at ASCO, including mature...
Kura Oncology Logo
Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results
25 févr. 2020 16h03 HE | Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 – – Company preparing to initiate a...
Kura Oncology Logo
Kura Oncology to Participate in Three Upcoming Investor Conferences
19 févr. 2020 16h05 HE | Kura Oncology, Inc.
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results
18 févr. 2020 16h05 HE | Kura Oncology, Inc.
SAN DIEGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology Announces Transition of Chief Medical Officer
23 janv. 2020 16h05 HE | Kura Oncology, Inc.
– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and medical affairs veteran...
Kura Oncology Logo
Kura Oncology to Present at J.P. Morgan Healthcare Conference
09 janv. 2020 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
06 janv. 2020 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial
16 déc. 2019 07h30 HE | Kura Oncology, Inc.
– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC – – Registration-directed AIM-HN trial expected to complete enrollment in first...